Recursion Pharmaceuticals, Inc. $RXRX Position Trimmed by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lowered its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 53.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 621,059 shares of the company’s stock after selling 718,080 shares during the period. Vestmark Advisory Solutions Inc. owned approximately 0.14% of Recursion Pharmaceuticals worth $3,031,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Brighton Jones LLC raised its position in shares of Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after purchasing an additional 6,699 shares during the period. Royal Bank of Canada increased its stake in Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after purchasing an additional 232,038 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth about $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after buying an additional 12,372 shares during the period. Finally, Focus Partners Wealth purchased a new stake in Recursion Pharmaceuticals during the first quarter valued at about $77,000. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $3.41 on Tuesday. The company has a market capitalization of $1.77 billion, a PE ratio of -1.89 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The company’s 50 day moving average price is $4.23 and its 200 day moving average price is $4.74. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.98 and a 52 week high of $9.74.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 220,000 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the transaction, the director directly owned 6,429,863 shares of the company’s stock, valued at approximately $27,005,424.60. This represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Najat Khan sold 124,403 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares in the company, valued at $2,695,105.35. This trade represents a 16.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 819,212 shares of company stock valued at $3,523,950. 8.43% of the stock is owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.